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Evaluation of Infusion Reactions Associated with Intravenous Immune
Globulin in Neonatal and Pediatric Patients
Katie Couch, PharmD; Samantha Tatz, PharmD, BCPS
Background

Discussion

• Intravenous immune globulin (IVIG) is used to
treat a variety of conditions such as hemolytic
disease of the newborn, Kawasaki disease, toxic
shock syndrome, various autoimmune disorders,
and infectious processes.
• The current practice for administering IVIG is a
titrated approach where initial rates of
administration and titration parameters are
specific to each IVIG product as recommended
by the manufacturer.
• Titration is recommended due to infusion
reactions including flushing, fever, changes in
pulse rate, and changes in blood pressure—all
which are suspected to increase as the infusion
rate increases.
• Most infusion reactions are mild and transient,
and more severe reactions such as anaphylaxis,
aseptic meningitis, and thrombosis are rare.
• Known risk factors for infusion reactions include
advanced age and renal failure, but with limited
data about infusion reactions in pediatric
patients, there may be risk factors not yet shown
to have statistical significance.

• A total of 70 patients received IVIG infusions.
• Eight patients (11.4%) experienced infusion
reactions despite pre-medication, all of which
were in pediatric patients between the ages of
29 days and 18 years (p=0.005).
• Administering IVIG at rates greater than 2
mL/kg/hr did not have a significant increase in
the number of infusion reactions.
• Additionally, there was no difference in the
number of infusion reactions between sex, doses
of IVIG greater than 1 g/kg, or among the three
IVIG brands (Gammagard, Gamunex-C,
Flebogamma).
• There was a significant difference in adverse
events between indications, with infectious
indications having the highest incidence
(p=0.0003).
• The median time from onset of infusion reaction
after IVIG initiation was 2 hours.
• The most common reactions were hypotension
(27%), tachycardia (18%), and fever (18%).
• Infusion reactions were managed by decreasing
the rate of the infusion (63%), temporarily
stopping the infusion (13%), or administering
rescue medications (13%).
• Among the pediatric subgroup, there was no
significant difference in infusion reactions
between sex, infusion rate, or dose.

Purpose
• To investigate possible risk factors influencing
the occurrence of IVIG-associated infusion
reactions

Objectives
Primary objective
• To assess infusion reactions to conclude whether
they were associated with higher infusion rates
of IVIG
Secondary objectives
• Rates of discontinuation or interruption of
therapy
• Symptoms of infusion reactions
• Use of rescue medications
• Infusion reaction incidence between brands,
dose, age, sex, and treatment indication

Results
Demographic Data
Variables
Age
≤28 days
29 days-18 years
Sex
Male
Female
Max Rate
≤2 mL/kg/hr
>2 mL/kg/hr
Unknown
Dose
≤1 g/kg
>1 g/kg
Indication
Hyperbilirubinemia
Kawasaki
Autoimmune
MIS-C
Infectious
Other
Premedication
Benadryl
Tylenol
Both
None
Brand
Gamunex-C
Gammagard
Flebogamma

All patients given IVIG Patients with infusion P-value
(n=70)
reactions (n=8)
0.005
34 (49)
0 (0)
36 (51)
8 (100)
0.462
33 (47)
5 (63)
37 (53)
3 (38)
0.430
22 (31)
4 (50)
42 (60)
4 (50)
6 (9)
0 (0)
0.113
46 (66)
3 (38)
24 (34)
5 (63)
0.0003
31 (44)
0 (0)
18 (26)
2 (25)
7 (10)
0 (0)
7 (10)
2 (25)
4 (6)
3 (38)
3 (4)
1 (13)
0.0002
6 (9)
1 (13)
7 (10)
2 (25)
20 (29)
5 (63)
37 (53)
0 (0)
0.464
23 (33)
1 (13)
25 (36)
4 (50)
22 (31)
3 (38)

Infusion Reactions
Time from onset of IVIG to reaction
Time
0-30 min
31-60 min
61 min-4 hr
5-9 hr
10-15 hr
16-24 hr
25 hr-1 week

Frequency (n=8)
0 (0)
0 (0)
7 (88)
0 (0)
0 (0)
0 (0)
1 (13)

Reaction incidence
Reaction
Hypotension
Tachycardia
Fever
Chills
Aseptic meningitis
Dizzy
Flushing

Frequency (n=11)
3 (27)
2 (18)
2 (18)
1 (9)
1 (9)
1 (9)
1 (9)

Methods
Study design
• Single-center, retrospective, observational study
at a large tertiary medical center
Statistical analysis
• Fisher’s exact test
• α = 0.05

Inclusion criteria
• Inpatient neonatal and pediatric patients who
received at least one dose of IVIG between
January 1, 2017 and December 31, 2021
Exclusion criteria
• Patients >18 years old

Prevention and Management
Prevention of infusion reactions
Pre-medications
Tylenol
Benadryl
Both
None

Frequency (n=8)
2 (25)
1 (13)
5 (63)
0 (0)

Study Limitations
• Retrospective, non-randomized study
• Select data was pulled from the electronic
health record via retrospective chart evaluation
by single reviewer
• Small study population with minimal infusion
reactions identified

Conclusion
• There was no association between infusion
reactions and higher IVIG infusion rates.
• Although patient age was the only variable found
to be associated with infusion reactions, findings
were potentially limited by the small study
sample size.
• Further research is required to evaluate risk
factors for infusion reactions and their
association with IVIG.

Disclosures

Management of infusion reactions
Interventions
Slowing down infusion rate
Temporarily stopping infusion
Rescue medications
No intervention

Frequency (n=8)
5 (63)
1 (13)
1 (13)
1 (13)

•
•
•
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